Therapeutic areas: Neurology
Post-Aduhelm controversy, Biogen reps are navigating a portfolio reset anchored by Leqembi (lecanemab) for early Alzheimer\
Key products: Leqembi, Tysabri, Plegridy, Skyclarys, Spinraza
Biogen reps use this room to compare neurology field reality, Leqembi access and infusion friction, interview process, compensation, and manager support.
Biogen reps use this room to compare neurology field reality, Leqembi access and infusion friction, interview process, compensation, and manager support.